AT-53 PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS WITH RECURRENT MALIGNANT GLIOBLASTOMA MULTIFORME (GBM)

Median survival for patients with recurrent GBM is <6 months. Front-line systemic therapy is temozolomide but resistance due to O6-methylguanine-DNA-methyltransferase (MGMT) activity is implicated in poor outcomes. Dianhydrogalactitol (VAL-083) is a structurally unique bi-functional DNA alkylatin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Shih, Kent, Patel, Manish, Butowski, Nicholas, Bacha, Jeffrey, Brown, Dennis, Garner, William, Steino, Anne, Schwartz, Richard, Kanekal, Sarath, Lopez, Lorena, Burris, Howard A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Adult Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217833/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.52
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados